Absci Collaborates with Oracle and AMD to Speed up AI-Led Drug Discovery, Shares Jump

Absci on Thursday announced a collaboration with Oracle Cloud Infrastructure and AMD to accelerate its AI-driven drug discovery efforts.

Absci shares jumped 9.5 in morning trading.

As part of the partnership, the Vancouver, Washington-based biotech will use Oracle’s AI infrastructure and AMD’s hardware for its generative AI Drug Creation Platform.

“This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI‑powered drug‑discovery workflows,” CEO Sean McClain remarked.

The announcement coincided with the Oracle Health and Life Sciences Summit taking place in Orlando, Florida, from Sept. 9 to 11.

During the event, the tech giant highlighted some of its healthcare-related advancements, including its AI capabilities within the Oracle Fusion Cloud Application, which it said could streamline supply chain operations within the industry.